abstract |
FIELD: medicine.SUBSTANCE: group of inventions refers to recurrent and refractory cancer treatment. Disclosed is the use of a composition comprising an antibody molecule which specifically binds to an antigen on a B cell surface and has an Fc domain capable of binding FcγRIIb in a subject having B-cells, expressing FcγRIIb, in combination with an agent which prevents or reduces binding of FcγRIIb presented on the surface of B-cell, with Fc-domain of this antibody molecule, and which prevents or reduces internalization of this antibody molecule into B-cell, for treating recurrent B-cell cancer and/or refractory B-cell cancer resistant to said antibody in a subject having B-cells expressing FcγRIIb. Also disclosed are use of the composition for producing a drug and a method of treating recurrent B-cell cancer and/or refractory B-cell cancer.EFFECT: group of inventions provides effective treatment for recurrent cancers and/or refractory cancer.42 cl, 28 dwg, 8 tbl, 2 ex |